Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma

Published:2023-12 Issue: Volume: Page:
ISSN:1424-3903
Container-title:Pancreatology
language:en
Short-container-title:Pancreatology

Author:

Wang Fenghua,Wang Yixing,Ren Chao,Li Xujia,Qiu Miaozhen,Li Yuhong,Luo Huiyan,Peng Ruojun,Quan Qi,Jiang Qi,Li Shengping,Guo Guifang

Funder

Natural Science Foundation of Guangdong Province

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Endocrinology, Diabetes and Metabolism

Reference31 articles.

1. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future;Christenson;Lancet Oncol,2020

2. Biomarkers for subtypes of pancreatic ductal adenocarcinoma;Venkatesan;Lancet Oncol,2017

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol : official journal of the American Society of Clinical Oncology,1997

4. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

5. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP